|
Lori,
That's very interesting. It seems like lots of the centers are trying different post-transplant drugs -- sometimes old ones -- to see what they can do about GVHD. Karen (Mausmish on this forum), who just did an STC at Johns Hopkins, had cytoxan afterwards in a clinical trial aimed at reducing GVHD.
One way to think about it is, if you wind up in the trial, the data you provide could help folks down the road.
Good luck!
Greg
__________________
Greg, 59, dx MDS RCMD Int-1 03/10, 8+ & Dup1(q21q31). NIH Campath 11/2010. Non-responder. Tiny telomeres. TERT mutation. Danazol at NIH 12/11. TX independent 7/12. Pancreatitis 4/15. 15% blasts 4/16. DX RAEB-2. Beginning Vidaza to prep for MUD STC. Check out my blog at www.greghankins.com
|